Dashboard
Manage Tickers

XERS Xeris Biopharma Holdings, Inc.

Nasdaq xerispharma.com


$ 9.17 $ -0.26 (-2.78 %)    

Tuesday, 21-Oct-2025 19:25:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 610.29 $ -0.16 (-0.03 %)
DIA $ 469.10 $ 2.20 (0.47 %)
SPY $ 670.98 $ -0.01 (0 %)
TLT $ 91.99 $ 0.45 (0.49 %)
GLD $ 376.61 $ -25.91 (-6.43 %)
$ 9.08
$ 9.28
$ 9.08 x 1
$ 9.17 x 14
$ 9.01 - $ 9.29
$ 2.82 - $ 9.41
1,979,852
na
1.47B
$ 1.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-06-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

american-regent-and-xeris-pharmaceuticals-launch-gvoke-vialdx-first-concentrated-liquid-glucagon-for-diagnostic-gi-procedures
American Regent And Xeris Pharmaceuticals ...
08/27/2025 12:39:20

First concentrated, ready-to-dilute liquid glucagon available for diagnostic proceduresSHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire...

xeris-announces-us-patent-listing-in-orange-book-extending-recorlev-protection-to-2040-for-endogenous-cushings-syndrome-treatment
Xeris Announces US Patent Listing In Orang...
08/25/2025 11:12:08

hc-wainwright--co-assumes-xeris-biopharma-holdings-at-buy-announces-price-target-of-10
HC Wainwright & Co. Assumes Xeris Biopharm...
08/12/2025 11:30:57

HC Wainwright & Co. analyst Brandon Folkes assumes Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy rating and announce...

xeris-biopharma-holdings-raises-fy2025-sales-guidance-from-260000m-275000m-to-280000m-290000m-vs-269380m-est
Xeris Biopharma Holdings Raises FY2025 Sal...
08/07/2025 11:05:31

xeris-biopharma-holdings-q2-eps-001-beats-002-estimate-sales-71539m-beat-64575m-estimate
Xeris Biopharma Holdings Q2 EPS $(0.01) Be...
08/07/2025 11:04:45

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

oppenheimer-maintains-outperform-on-xeris-biopharma-holdings-raises-price-target-to-7
Oppenheimer Maintains Outperform on Xeris ...
05/09/2025 17:51:53

Oppenheimer analyst Leland Gershell maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price ...

xeris-biopharma-holdings-raises-fy2025-sales-guidance-from-25500m-27500m-to-26000m-27500m-vs-31763m-est
Xeris Biopharma Holdings Raises FY2025 Sal...
05/08/2025 11:07:05

xeris-biopharma-holdings-q1-eps-006-misses-004-estimate-sales-6012m-miss-6265m-estimate
Xeris Biopharma Holdings Q1 EPS $(0.06) Mi...
05/08/2025 11:01:33

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

earnings-outlook-for-xeris-biopharma-holdings
Earnings Outlook For Xeris Biopharma Holdings
05/07/2025 15:02:14

xeris-announces-fda-approval-of-supplemental-new-drug-application-of-gvoke-vialdx-for-use-as-a-diagnostic-aid-xeris-also-announced-it-has-partnered-with-american-regent-to-commercialize-gvoke-vialdx-financial-terms-were-not-disclosed
Xeris Announces FDA Approval Of Supplement...
03/17/2025 12:10:39

First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology marketAmerican Regent to ...

piper-sandler-reiterates-neutral-on-xeris-biopharma-holdings-raises-price-target-to-4
Piper Sandler Reiterates Neutral on Xeris ...
03/07/2025 15:42:48

Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Neutral and raises the price t...

hc-wainwright--co-reiterates-buy-on-xeris-biopharma-holdings-raises-price-target-to-8
HC Wainwright & Co. Reiterates Buy on Xeri...
03/07/2025 11:50:49

HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the pric...

xeris-biopharma-expects-2025-revenue-of-255m-275m-representing-growth-of-over-30-at-the-mid-point-of-the-range-versus-consensus-of-23984m
Xeris Biopharma Expects 2025 Revenue Of $2...
03/06/2025 12:05:52

xeris-biopharma-holdings-q4-2024-gaap-eps-003-beats-006-estimate-sales-6010m-beat-5810m-estimate
Xeris Biopharma Holdings Q4 2024 GAAP EPS ...
03/06/2025 12:01:51

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate...

earnings-scheduled-for-march-6-2025
Earnings Scheduled For March 6, 2025
03/06/2025 08:32:20

jefferies-reiterates-buy-on-xeris-biopharma-holdings-raises-price-target-to-6
Jefferies Reiterates Buy on Xeris Biopharm...
02/03/2025 15:29:00

Jefferies analyst Glen Santangelo reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price target f...

american-diabetes-association-and-xeris-biopharma-holdings-announce-multi-year-partnership-to-promote-ready-to-use-glucagon-for-individuals-with-diabetes-on-blood-glucose-lowering-medications-following-updated-2025-standards-of-care
American Diabetes Association And Xeris Bi...
01/21/2025 14:04:58

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should ha...

xeris-biopharma-expects-to-generate-2024-revenue-of-203m-exceeding-previous-guidance-of-198m-202m-versus-consensus-of-19970m-with-over-71m-in-cash-cash-equivalents-and-short-term-investments-generating-positive-cash-flow-in-the-fourth-quarter
Xeris Biopharma Expects To Generate 2024 R...
01/10/2025 12:17:39

Other Fourth Quarter 2024 UpdatesRecorlev achieved record number of new starts and referrals.Gvoke ended the year with approxim...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION